Microarray profiling analysis of lncRNAs expression in gastric cancer specimens
Ontology highlight
ABSTRACT:
PROVIDER: PRJNA613241 | ENA |
REPOSITORIES: ENA
Similar Datasets
Project description:Growing evidence has indicated that LncRNA CYTOR involved in the initiation and progression of malignancy, such as gastric cancer, hepatocellular carcinoma, renal cell carcinoma, and colorectal cancer. Nevertheless, the mechanisms of CYTOR in the development of metastatic gastric cancer remains unknown. In the current study, the authors clarified the association of CYTOR/miR-103/RAB10 was implicated in cancer metastasis. CYTOR expression evaluated in metastatic gastric cancer biopsies compared to the primary cases. Moreover, CYTOR expression correlated with the invasiveness, lymph node metastasis, and advanced stages of gastric cancer. Downregulation of CYTOR by shRNA hampered proliferation and migration, while induced cell apoptosis significantly. MicroRNA miR-103 was related to CYTOR expression negatively. Furthermore, dual-luciferase reporter assay confirmed that CYTOR sponged miR-103 and diminished miR-103 expression. Expression of Ras-related protein RAB10 was downregulated by miR-103, leading to the attenuation of cell migration and proliferation. The deregulated CYTOR cells were produced and subsequently injected into mice subcutaneously. The tumor growth decreased significantly in the CYTOR knockdown group, compared to the vehicle group. Briefly, the present findings suggested that CYTOR -miR-103-RAB10 was a novel promising pathway for conquering gastric cancer progression. Long noncoding RNA profiling by array
2020-03-19 | GSE147167 | GEO
Project description:Long noncoding RNAs (LncRNAs) are an important class if pervasive genes involved in a variety of biological functions. LncRNAs have been recently implicated as having oncogenic and tumor suppressor roles. To further investigate the function of lncRNA in gastric cancer, we use lncRNA microarray to describe LncRNAs profiles in 6 pairs of human gastric adenocarcinoma and the corresponding adjacent nontumorous tissues. The experimental samples are divided into two groups(normal and tumor) to compare lncRNA expression profiling of those
2013-12-09 | E-GEOD-53137 | biostudies-arrayexpress
Project description:Long noncoding RNAs (LncRNAs) are an important class if pervasive genes involved in a variety of biological functions. LncRNAs have been recently implicated as having oncogenic and tumor suppressor roles. To further investigate the function of lncRNA in gastric cancer, we use lncRNA microarray to describe LncRNAs profiles in 6 pairs of human gastric adenocarcinoma and the corresponding adjacent nontumorous tissues.
2013-12-09 | GSE53137 | GEO
Project description:We implemented lncRNA microarray analysis in 5 paired gastric cancer tissues and adjacent noncancerous tissues to identify differential expression of lncRNAs and mRNAs in gastric cancer.
2021-04-14 | GSE157289 | GEO
Project description:Long noncoding RNAs (lncRNAs), which are noncoding RNAs (ncRNAs) with length more than 200 nucleotides (nt), have been demonstrated to be involved in various types of cancer. In this study, a custom designed microarray platform covering both mRNAs and lncRNAs was applied to tumor tissues of gastric, colon, liver and lung. 316 and 157 differential expressed (DE-) protein coding genes and lncRNAs common to these four types of cancer were identified respectively.
2017-02-09 | GSE70880 | GEO
Project description:To explor the role of lncRNAs in gastric cancer progression, we performed a microarray analysis to systematically screen the differential expression of lncRNAs between six human gastric cancer tissues and their matched non-tumor tissues
2018-12-03 | GSE106815 | GEO
Project description:Exosomes from the culture media (CM) of four GC cells (GCCs) and human gastric epithelial cells were isolated. Exosomal RNA was extracted, and lncRNA microarray assay was performed to identify GC-specific exosomal lncRNAs. A total of 199 exosomal lncRNAs were expressed at considerable higher levels in GCCs than those in normal controls, among which the top 10 upregulated lncRNAs were selected for further validation. qRT-PCR revealed that lnc-SLC2A12-10:1 was remarkably upregulated in exosomes derived from patients with GC and GCCs. The expression levels of the candidate exosomal lncRNAs lnc-SLC2A12-10:1 were validated in 120 subjects via quantitative reverse transcription PCR (qRT-PCR).The result suggested that exosomal lnc-SLC2A12-10:1 may be a potential noninvasive biomarker for the diagnosis and prognosis monitoring of GC.
2020-06-04 | GSE148334 | GEO
Project description:Total RNA was extracted from human gastric cancer tissues (n=4) and matched adjacent normal tissues (n=4) . RNA samples were analyzed by RNA sequencing based on the manufacturer’s protocols. Briefly, Illumina HiSeq 4000 platform was used to sequence the RNA samples for the subsequent generation of raw data. R package was utilized to select lncRNAs with significantly differential expression based on fold change >2 or <1/2, p value <0.05 between human gastric cancer tissues and matched adjacent normal tissues, and the top 10 upregulated lncRNAs were selected for further study.
2022-10-12 | GSE172032 | GEO
Project description:Microarray profiling analysis of lncRNAs expression in glioma cells
| PRJNA604907 | ENA
Project description:Long non-coding RNAs (lncRNAs) can serve as blood-based biomarkers for cancer detection. To identify novel lncRNA biomarkers for gastric cancer (GC), we conducted, for the first time, genome-wide lncRNA screening analysis in two sets of samples: five paired preoperative and postoperative day 14 plasma samples from GC patients, and tissue samples from tumor and adjacent normal tissues. Candidate tumor-related lncRNAs were then quantitated and evaluated in three independent phases comprising 321 participants. The expression levels of lncRNAs were also measured in GC cell lines and the corresponding culture medium. Biomarker panels, lncRNA-based Index I and carcinoembryonic antigen (CEA)-based Index II, were constructed using logistic regression, and their diagnostic performance compared. Fagan's nomogram was plotted to facilitate clinical application. As a result, we identified five novel plasma lncRNAs (TINCR, CCAT2, AOC4P, BANCR and LINC00857), which, when combined in the lncRNA-based Index I, outperformed the CEA-based Index II (P < 0.001) and could distinguish GC patients from healthy controls with an area under the receiver-operating curve (AUC) of 0.91 (95% confidence interval (CI): 0.88-0.95). The lncRNA-based index decreased significantly by postoperative day 14 (P = 0.016), indicating its ability to monitor tumor dynamics. High values of the lncRNA-based index were correlated with tumor size (P = 0.036), depth of invasion (P = 0.025), lymphatic metastasis (P = 0.012) and more advanced tumor stages (P = 0.003). The lncRNA-based index was also able to discriminate GC patients from precancerous individuals and patients with gastrointestinal stromal tumor with AUC values of 0.82 (95% CI: 0.71-0.92) and 0.80 (95% CI: 0.68-0.91), respectively. Taken together, our findings demonstrate that this panel of five plasma lncRNAs could serve as a set of novel diagnostic biomarkers for GC detection.
| S-EPMC5196898 | biostudies-literature